10 Best Biotech Stocks To Buy Under $20

4. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Number of Hedge Fund Holders: 33

Price: $11.66

Iovance Biotherapeutics Inc (NASDAQ:IOVA) is a commercial-stage biotechnology company focused on developing innovative cell therapies using autologous tumor-infiltrating lymphocytes (TILs) for the treatment of metastatic melanoma and other solid tumors.

The company’s primary product, Amtagvi is a cell therapy for advanced melanoma. It is expected to be the primary driver of growth through the end of the decade. Since its approval in the first quarter of 2024, Amtagvi has been successfully launched, generating $31.1 million in sales during the second quarter.

Iovance Biotherapeutics Inc’s (NASDAQ:IOVA) revenue is forecasted to reach as much as $475 million in the fiscal year 2025. To support this growth, the company is pursuing regulatory approval in international markets, including the European Union, with decisions expected in early 2025. Given the significant growth potential and anticipated future approvals, investing in Iovance Biotherapeutics Inc (NASDAQ:IOVA) now may be a wise decision, as the stock price is likely to appreciate over the long term.

Here’s what Artisan Partners said about Iovance Biotherapeutics Inc (NASDAQ:IOVA)  in its Q1 2024 investor letter:

“Among our top performers in Q1 were Shockwave, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and Wingstop. Iovance Biotherapeutics is a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for cancer patients. Immuno-oncology remains a key area of drug development, and Iovance is the leader in TIL development and manufacturing, having secured the technology through collaborations with the leading academic institutions in TIL research. Shares rallied significantly after the company announced that the FDA approved AMTAGVI™ (lifileucel) for advanced melanoma. We added to the position.”